PET Imaging of a Marker for Breast Cancer Metastasis
Abstract
The serine protease matriptase has been implicated in epithelial cancers, and has been indicated as a biomarker for survival independent of HER-2/neu. While in vitro methods are invaluable, few breast cancer cell lines express matriptase, though a majority of breast cancers are positive for matriptase-this suggests that imaging the in vivo behavior of matriptase may aid in understanding its context in a tumor system. Specifically, activated matriptase is associated with cancer progression. We have developed tracers against activated matriptase for in vivo imaging using PET. M69 antibody (against activated matriptase) was functionalized to capture [64Cu]copper: 64Cu-TETA-M69 was evaluated in mouse models of human breast cancer. In a tet-regulable model for human matriptase expression, with confirmation from IHC, we found marker specific tumor retention through biodistribution and PET imaging. In summary, we have developed a novel radiotracer for the first imaging of activated matriptase in vivo, demonstrating favorable pharmacokinetics. This approach has the potential for imaging metastasis, the primary cause of mortality in breast cancer patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2010
- Accession Number
- ADA520724
Entities
People
- Julia Choi
Organizations
- University of California